Jan Mikkelsen, Ascendis Pharma president and CEO

Af­ter first FDA win last year, As­cendis touts a new PhI­II suc­cess in hy­poparathy­roidism

Af­ter achiev­ing its first FDA ap­proval last sum­mer, As­cendis Phar­ma be­lieves it’s ap­proach­ing a sec­ond in the near fu­ture.

The Dan­ish biotech tout­ed topline Phase III da­ta for a hy­poparathy­roidism pro­gram Sun­day evening, say­ing it met the pri­ma­ry end­point and all key sec­ondary end­points. As such, the com­pa­ny plans to sub­mit an NDA in the third quar­ter and al­so file for Eu­ro­pean ap­proval by the end of the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.